"Development of biglycan as a therapeutic for Duchenne Muscular Dystrophy"

“开发双聚糖治疗杜氏肌营养不良症”

• 批准号: 8136541
• 负责人: JUSTIN R. FALLON
• 金额: $ 133.65万
• 依托单位: BROWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-08-01 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8136541
• 关键词: Development; biglycan; therapeutic; Duchenne; Muscular

DESCRIPTION (provided by applicant): This U01 Translational Research in Muscular Dystrophy will support the development of recombinant human biglycan (rhBGN) as a therapeutic and to prepare the data package necessary for an IND filing with the FDA. It builds upon work supported by an exploratory R21 proposal to our laboratory where we have demonstrated that systemically-delivered, rhBGN counters the dystrophic phenotype in mdx mice and improves muscle function. Notably, rhBGN is effective when delivered at 3 week intervals and at doses of <10mg/kg. We propose a 4 year development plan to produce and to validate rhBGN material that is compatible with use in clinical trials. This plan will extend from pilot studies with material produced by transient transfection, to PK/PD in the mdx mouse model, to dose optimization with highly characterized material produced from a stable cell line under cGMP conditions. To maximize the efficiency and speed of this process, the work will make use of standardized models and assays as well as collaborations with several expert vendors of biologic development services. We have also enlisted consultants who have extensive expertise in the manufacturing, testing and regulatory issues that are unique to biologies. PUBLIC HEALTH RELEVANCE: In these translational studies we will develop a novel protein therapeutic for Duchenne Muscular Dystrophy. The goal is to take our findings in mouse models of this disease and do the work necessary to test this therapy in boys with this devastating disease. If the proposed work is successful, we will be able to move immediately into Phase I clinical trials.

描述（由申请人提供）：本U 01肌营养不良转化研究将支持重组人双糖链蛋白聚糖（rhBGN）作为治疗药物的开发，并准备向FDA提交IND申请所需的数据包。它建立在我们实验室的探索性R21提案支持的工作基础上，我们已经证明了系统递送的rhBGN对抗mdx小鼠中的营养不良表型并改善肌肉功能。值得注意的是，当以3周的间隔和<10 mg/kg的剂量递送时，rhBGN是有效的。我们提出了一个4年的开发计划，以生产和验证与临床试验兼容的rhBGN材料。该计划将从使用瞬时转染产生的材料的初步研究扩展到mdx小鼠模型中的PK/PD，再到使用在cGMP条件下从稳定细胞系产生的高度表征的材料进行剂量优化。为了最大限度地提高这一过程的效率和速度，这项工作将利用标准化的模型和分析，以及与生物开发服务的几家专家供应商的合作。我们还聘请了在生物制品特有的制造、测试和监管问题方面拥有广泛专业知识的顾问。 公共卫生相关性：在这些转化研究中，我们将开发一种治疗杜氏肌营养不良症的新型蛋白质治疗剂。我们的目标是利用我们在这种疾病的小鼠模型中的发现，并在患有这种毁灭性疾病的男孩中进行必要的测试。如果拟议的工作成功，我们将能够立即进入I期临床试验。